市場調査レポート

商品コード

北米の感染症向けPOC市場規模・予測、地域シェア、動向、成長機会分析レポート

North America Point-of-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis Report

出版日: 2024年05月24日
発行: The Insight Partners
ページ情報: 英文 162 Pages
納期: 即納可能

価格

PDF (Single User License)

USD 3,450 521,640円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 4,450 672,840円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 5,450 824,040円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=151.20円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

北米の感染症用ポイントオブケア分子検査の世界市場は、2023年の10億9,000万米ドルから2031年には26億3,000万米ドルに達すると予測されます。2023年から2031年までのCAGRは11.1%で成長すると推定されます。

本レポートで紹介する北米の感染症用ポイントオブケア分子検査市場予測は、同マーケットプレースの利害関係者が成長戦略を計画するのに役立ちます。感染症の急増と迅速診断ソリューションへの嗜好が市場開拓を推進する主な要因です。しかし、不十分な償還シナリオが北米の感染症用ポイントオブケア分子検査市場の成長を阻害しています。

北米の感染症用ポイントオブケア分子検査市場の市場機会

研究開発（R&D）は製薬・バイオ医薬品企業にとって不可欠な要素です。研究開発により、市場参入企業は、医学的・商業的に大きな可能性を秘めたさまざまな治療用途の新製品を開発することができます。以下の表は、NIHが採用している契約、助成金、その他の資金調達メカニズムに基づく、さまざまな研究および疾患カテゴリーに対する年間資金を示したものです。

表1.感染症と資金提供

2019年（百万米国ドル） 2020年（百万米国ドル） 2021年（百万米国ドル） 2022年（百万米国ドル）

新興感染症2,950 4,867 5,069 4,318

感染症6,313 8,301 8,599 8,019

性感染症354 394 404 419

注：通貨は現在の換算レートを用いています。

出典年次報告書およびインサイト・パートナーズ分析

感染症患者の増加と相まって、検査能力や分子検査試薬の不足に対応するため、診断検査メーカー各社は、検査室外での検査を容易にするため、迅速で使いやすい機器を提供しています。以下は、北米の感染症用POC市場でメーカーが行っている主な資金調達の取り組みのリストです。

8月、米国保健福祉省（HHS）は、戦略的準備・対応局（Administration for Strategic Preparedness and Response）の一部門である生物医学先端研究開発局（Biomedical Advanced Research and Development Authority：BARDA）のもと、キューヘルス社に2,800万米ドル相当の新規契約を発注しました。この契約は、COVID-19、呼吸器合胞体ウイルス（RSV）、インフルエンザA/Bの診断のためのポイントオブケア（POC）および店頭販売（OTC）目的で使用できる分子多重検査を開発するために提示されました。Cue社の検査は、COVID-19、呼吸器合胞体ウイルス（RSV）、インフルエンザA、インフルエンザBを同時に検出・鑑別し、リンクされたスマートデバイスに約25分で結果を提供します。

2023年1月、非営利の行動科学イニシアチブ・グループである19 to Zeroは、プライマリ・ケア環境におけるポイント・オブ・ケア検査の試験的実施のため、教育助成金を通じてBDから資金提供を受けた。インフルエンザAおよびB、RSV、SARS-CoV-2、A群溶連菌、三種混合菌のポイントオブケア診断検査を促進するため、複数のBDベリタープラスシステムアナライザーとBDベリターシステム迅速検出アッセイの提供を伴う資金援助を受けました。

2022年3月、世界エイズ・マラリア・結核対策基金は、カナダが世界基金のCOVID-19対応メカニズム（C19RM）に6,000万カナダドル（4,399万米ドル）を拠出することを決定したと発表しました。この資金は、救命のための診断検査、治療、個人防護具（PPE）を中低所得国に提供する取り組みを支援するために提供されました。

2021年9月、バイデン-ハリス政権は、米国の公衆衛生およびヘルスケア部門全体の感染制御および予防活動を強化するために21億米ドルを投資しました。バイデン-ハリス政権は、CDCを通じて、米国の救済プログラムに投資し、米国の感染症に関する州、地方、地域の保健部門やその他のパートナー組織に対処しました。

このように、感染症診断における研究開発と資金調達への注目の高まりは、今後数年間、北米の感染症向けPOC市場の成長に有利な機会を生み出すと期待されています。

北米感染症向けPOC市場の阻害要因

新しい検査の費用対効果を示さない、あるいは既存の検査が高価であることを証明しないデータが存在する場合、償還の可能性は低いままです。したがって、ほとんどの診断検査に対する償還率が低いため、製造企業は新しい検査の開発に大きな資源を投資することができないです。新しい、あるいは高価な診断検査に対する償還の難しさや懸念は、診断技術の普及に大きな課題をもたらしています。米国では、第三者支払機関が医療サービスや病態をコード化し、支払水準を決定することで保険償還が成り立っています。CPT（Current Procedural Terminology）コードによる外来検査については、Medicare Coverage Advisory Committeeが、十分なエビデンスと健康上の有益性の判断を含め、診断検査の適用についてメディケア＆メディケイドサービスセンター（CMS）に働きかけています。しかし、メディケアの払い戻しに関する決定は、全国的ではなく地域的に行われることがほとんどです。診断検査の適用範囲は地域によって異なります。また、保険適用を決定する際の基準がないため、新しい診断薬の開発と入手が困難になることもあります。

場合によっては、償還金が検査費用をカバーしないため、検査室が検査を提供することが制限され、検査の利用可能性と使用が減少します。また、検査費用は高くても患者負担が大きいため、医師が日常的に検査を依頼することができない場合もあります。

疾患別に見ると、北米の感染症向けPOC市場は、HIV検査、インフルエンザ検査、性感染症検査、C型肝炎ウイルス検査、熱帯病検査、呼吸器感染症検査、院内感染、溶連菌検査、その他に分けられます。市場はさらに、分子診断学に基づいてポリメラーゼ連鎖反応（PCR）、等温核酸増幅技術（INAAT）、その他に分けられます。2023年には呼吸器感染症検査分野が最大の市場シェアを占めました。

技術別では、市場はラテラルフローアッセイ、ディップスティック、マイクロ流体、分子診断、イムノアッセイ、固相、その他に区分されます。ラテラルフローアッセイ分野は2023年に市場で最大のシェアを占めました。

サンプルに関しては、市場は血液サンプル、尿サンプル、鼻腔・口腔咽頭スワブ、その他に区分されます。2023年には血液サンプル分野が最大の市場シェアを占めています。

エンドユーザー別では、市場は病院・診療所、在宅ケア環境、外来・緊急ケア施設、老人ホーム・福祉施設、研究室、診断センターに区分されます。病院・診療所市場はさらに、臨床検査室、専門医事務所、その他に分けられます。病院・診療所セグメントが2023年に最大の市場シェアを占めました。

北米の感染症向けポイントオブケア分子検査市場地域別概要

感染症の有病率の増加、高齢者人口の増加、主要企業による製品上市数の急増が、米国における感染症用ポイントオブケア検査市場成長の主な要因です。60歳以上の高齢者は免疫力が低下している可能性があるため、高齢化は感染症の顕著なリスク要因です。人口問題研究所が2020年に発表した調査によると、米国における65歳以上の人口は2020年には5,500万人、2060年には9,500万人に達すると予測されています。米国の規制当局は、ポイントオブケア（POC）検査製品の開発を厳しく監視しています。例えば、2021年3月、米国食品医薬品局（FDA）はBinx Health IO CT/NG Assayを地域密着型クリニック、緊急医療環境、外来医療施設向けに認可しました。

北米の感染症用POC分子検査市場に関する報告書を作成する際に参照した主な一次情報および二次情報には、世界銀行データ、国民保健サービス（NHS）、米国保健福祉省（HHS）、WHO（世界保健機関）などがあります。

北米の感染症向けPOC分子検査市場：主要市場力学
市場促進要因
- 感染症の急増
- 迅速診断ソリューションへの嗜好
市場抑制要因
- 不十分な償還シナリオ
市場機会
- 感染症診断における研究開発および資金調達への注目の高まり
今後の動向
- 承認・上市数の増加
促進要因と抑制要因の影響

第6章北米の感染症向けPOC市場分析

北米の感染症向けPOC市場売上高、2021年～2031年
北米の感染症向けPOC市場予測・分析
市場シェア分析、企業別（2023年）
価格分析
COVID-19前後の影響
製品/企業の知的財産権
- POC特許出願
感染症向けPOC検査市場への新規参入企業

第7章北米の感染症向けPOC分子検査市場分析-疾患別

HIV検査
インフルエンザ検査
性感染症検査
C型肝炎ウイルス検査
熱帯病検査
呼吸器感染症検査
院内感染
溶連菌検査
その他

第8章北米の感染症向けPOC市場分析-技術別

ラテラルフローアッセイ
ディップスティック
マイクロフルイディクス
分子診断薬
イムノアッセイ
固相
その他

第9章北米感染症向けPOC市場分析-処方箋検査別

処方箋ベースの検査
OTC検査

第10章北米の感染症用POC市場分析-検体別

血液サンプル
尿サンプル
鼻腔および口腔咽頭スワブサンプル
その他

第11章北米の感染症向けPOC市場分析：エンドユーザー別

病院および診療所
在宅医療施設
外来および救急医療施設
老人ホームおよび福祉施設
研究機関
診断センター

第12章北米の感染症向けPOC市場分析：流通チャネル別

E-Comプラットフォーム
小売チャネルと薬局
その他

第13章北米の感染症向けPOC市場：国別分析

北米
- 米国
- カナダ
- メキシコ

第14章北米の感染症向けPOC市場：業界情勢

北米の感染症向けPOC市場における成長戦略
有機的成長戦略
無機的成長戦略

第15章企業プロファイル

Abbott Laboratories
Agilent Technologies Inc
Becton Dickinson and Co
Bio-Rad Laboratories Inc
Cardinal Health Inc
Danaher Corp
Cue Health Inc
QuidelOrtho Corp
Thermo Fisher Scientific Inc
F. Hoffmann-La Roche Ltd

第16章付録

図表

List Of Tables

Table 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation
Table 2. Infectious Diseases and Fundings
Table 3. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Table 4. Market Share Analysis, By Companies (2023)
Table 5. Pricing Analysis
Table 6. List of Patent filed by Companies
Table 7. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
Table 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
Table 9. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
Table 10. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
Table 11. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
Table 12. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
Table 13. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
Table 14. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
Table 15. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 16. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals and Clinics
Table 17. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
Table 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Country
Table 19. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
Table 20. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
Table 21. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
Table 22. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
Table 23. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
Table 24. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
Table 25. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
Table 26. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
Table 27. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 28. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
Table 29. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
Table 30. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
Table 31. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
Table 32. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
Table 33. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
Table 34. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
Table 35. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
Table 36. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
Table 37. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
Table 38. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 39. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
Table 40. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
Table 41. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Diseases
Table 42. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
Table 43. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
Table 44. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
Table 45. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
Table 46. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
Table 47. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Prescription Testing
Table 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sample
Table 49. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 50. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals And Clinics
Table 51. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
Table 52. Recent Organic Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
Table 53. Recent Inorganic Growth Strategies in the North America Point-Of-Care Molecular Testing For Infectious Diseases Market
Table 54. Glossary of Terms, Infectious Disease Diagnostics Market
- 1.1.2

List Of Figures

Figure 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021-2031
Figure 5. Pre and Post COVID-19 Impact
Figure 6. Patents filed by Top Companies for POC
Figure 7. Number of Patent Families for POC
Figure 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Diseases, 2023 and 2031
Figure 9. HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Technology, 2023 and 2031
Figure 19. Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 25. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Prescription Testing, 2023 and 2031
Figure 27. Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Sample, 2023 and 2031
Figure 30. Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 31. Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 33. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 34. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by End User, 2023 and 2031
Figure 35. Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 36. Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 37. Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 38. Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 39. Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 40. Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 41. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 42. E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 43. Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 44. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 45. North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 46. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 47. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
Figure 49. Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market

Product Code: TIPRE00039163

The global North America point-of-care molecular testing for infectious diseases market is expected to reach US$ 2.63 billion in 2031 from US$ 1.09 billion in 2023. The market is estimated to grow with a CAGR of 11.1% from 2023 to 2031.

The North America point-of-care molecular testing for infectious diseases market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. The surging prevalence of infectious diseases and preference for rapid diagnostic solutions are the key factors propelling the market development. However, inadequate reimbursement scenarios impede the North America point-of-care molecular testing for infectious diseases market growth.

Market Opportunities of North America Point-Of-Care Molecular Testing For Infectious Diseases Market

Research and development (R&D) is an essential component of pharmaceutical and biopharmaceutical companies. R&D enables market players to develop new products for various therapeutic applications with significant medical and commercial potential. The following table displays the annual funding for various research and disease categories based on contracts, grants, and other funding mechanisms adopted by the NIH.

Table 1. Infectious Diseases and Fundings

Research/Disease Areas 2019 (US$ Million) 2020 (US$ Million) 2021 (US$ Million) 2022 (US$ Million)

Emerging Infectious Diseases 2,950 4,867 5,069 4,318

Infectious Diseases 6,313 8,301 8,599 8,019

Sexually Transmitted Infections 354 394 404 419

Note: The current conversion rate is considered for the currencies.

Source: Annual Reports and The Insight Partners Analysis

In response to the shortage of laboratory capabilities and molecular testing reagents, coupled with the rising cases of infectious diseases, diagnostic testing manufacturers offer fast and easy-to-use devices to facilitate out-of-laboratory testing. Following is a list of a few key funding initiatives undertaken by manufacturers in the North America point-of-care testing for infectious diseases market.

In August, the US Department of Health and Human Services (HHS) awarded Cue Health a new contract worth ~US$ 28 million under the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response. The contract was presented to develop a molecular multiplex test that can be used for point-of-care (POC) and over-the-counter (OTC) purposes for COVID-19, respiratory syncytial virus (RSV), and influenza A/B diagnoses. Cue's test would provide results to linked smart devices in nearly 25 minutes, simultaneously detecting and differentiating between COVID-19, respiratory syncytial virus (RSV), influenza A, and influenza B.

In January 2023, 19 to Zero, a non-profit behavioral sciences initiative group, received financing from BD through an educational grant for a point-of-care testing pilot in the primary care environment. A financial award was accompanied by the provision of multiple BD Veritor Plus System Analyzers and BD Veritor System for Rapid Detection Assays to facilitate point-of-care diagnostic testing for influenza A and B, RSV, SARS-CoV-2, Group A Strep, and triplex.

In March 2022, the Global Fund to Fight AIDS, Malaria, and Tuberculosis acclaimed the decision by Canada to contribute CAD 60 million (US$ 43.99 million) to the Global Fund's COVID-19 Response Mechanism (C19RM). The funding was provided to support efforts made to provide life-saving diagnostic tests, treatments, and personal protective equipment (PPE) to low- and middle-income countries.

In September 2021, the Biden-Harris Administration invested US$ 2.1 billion to enhance infection control and prevention activities across the US public health and healthcare sectors. The Biden-Harris administration, operating through the CDC, invested in US rescue programs to address state, local, and territorial health departments and other partner organizations regarding infectious diseases in the US.

Thus, rising focus on R&D and funding in infectious disease diagnostics is expected to create lucrative opportunities for the growth of North American point-of-care testing in the infectious disease market in the coming years.

Factor Hampering North American Point-Of-Care Testing In The Infectious Disease Market

The possibility of reimbursement remains low if there exists data that does not indicate the cost-effectiveness of new tests or prove the existing tests are expensive. Thus, low reimbursement rates for most diagnostic tests discourage manufacturing companies from investing large resources in developing new tests. Difficulties and concerns about reimbursing new or expensive diagnostic tests pose significant challenges to the widespread deployment of diagnostic technologies. In the US, reimbursement comprises coverage by third-party payers coding health services or conditions to determine payment level. For outpatient tests with Current Procedural Terminology (CPT) codes, the Medicare Coverage Advisory Committee promotes the Centers for Medicare & Medicaid Services (CMS) regarding diagnostic test coverage, including determining sufficient evidence and health benefits. However, most Medicare reimbursement decisions are made locally and not nationally. Coverage for diagnostic tests differs as per region. Also, the lack of standards in determining coverage can challenge the development and availability of a new diagnostic product.

In some cases, the reimbursement does not cover test costs, which limits laboratories in offering the test and reduces test availability and use. In other cases, test charges may be high but may leave a considerable cost to the patient, which limits physicians from ordering the test routinely.

Based on disease, the North America point-of-care molecular testing for infectious diseases market is divided into HIV testing, influenza testing, sexually transmitted diseases testing, hepatitis C virus testing, tropical diseases testing, respiratory infection testing, hospital-acquired infections, strep, and others. The market is further divided on the basis of molecular diagnostics into polymerase chain reactions (PCR), isothermal nucleic acid amplification technology (INAAT), and others. The respiratory infection testing segment held the largest market share in 2023.

By technology, the market is segmented into lateral flow assay, dipsticks, microfluidics, molecular diagnostics, immunoassays, solid phase, and others. The lateral flow assay segment held the largest share of the market in 2023.

In terms of sample, the market is segmented into blood samples, urine samples, nasal and oropharyngeal swabs, and others. The blood sample segment held the largest market share in 2023.

In terms of end user, the market is segmented into hospitals and clinics, home care settings, ambulatory and urgent care facilities, nursing homes and assisted living facilities, research laboratories, and diagnostics centers. The market is further divided on the basis of hospitals and clinics into clinical laboratories, professional physician offices, and others. The hospitals and clinics segment held the largest market share in 2023.

North America Point-Of-Care Molecular Testing for Infectious Diseases Market: Regional Overview

The increasing prevalence of infectious diseases, the rising geriatric population, and a surging number of product launches by key players are the primary contributors to the point-of-care testing for infectious diseases market growth in the US. Aging is a prominent risk factor for infectious diseases, as people aged more than 60 may have compromised immunity. According to a study published by the Population Reference Bureau in 2020, the population of individuals aged 65 and above was 55 million in the US in 2020, and the number is expected to reach 95 million by 2060. Regulatory agencies in the US rigorously monitor the development of point-of-care (POC) testing products. For instance, in March 2021, the US Food Drug Administration (FDA) authorized Binx Health IO CT/NG Assay for community-based clinics, urgent care settings, and outpatient healthcare facilities; it is the first POC testing product for diagnosing chlamydial and gonorrheal infections.

A few of the major primary and secondary sources referred to while preparing the report on the North America point-of-care molecular testing for infectious diseases market are the World Bank Data, National Health Service (NHS), US Department of Health and Human Services (HHS), and WHO (World Health Organization).

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
3.3 Hypothesis formulation
- 3.3.1 Macro-economic factor analysis:
- 3.3.2 Developing base number:
- 3.3.3 Data Triangulation:
- 3.3.4 Country level data:

4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape

4.1 Overview
4.2 PEST Analysis

5. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Key Market Dynamics

5.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Surging Prevalence of Infectious Diseases
- 5.2.2 Preference for Rapid Diagnostic Solutions
5.3 Market Restraints
- 5.3.1 Inadequate Reimbursement Scenario
5.4 Market Opportunities
- 5.4.1 Increasing Focus on R&D and Funding in Infectious Disease Diagnostics
5.5 Future Trends
- 5.5.1 Rising Number of Product Approvals and Launches
5.6 Impact of Drivers and Restraints:

6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis

6.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021-2031
6.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Forecast and Analysis
6.3 Market Share Analysis, By Companies (2023)
6.4 Pricing Analysis
6.5 Pre and Post COVID-19 Impact
6.6 Intellectual Property Rights of Products/Companies
- 6.6.1 POC Patent Filing
6.7 Novel Companies Entering the Point of Care Testing Market For Infectious Diseases Application

7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Diseases

7.1 HIV Testing
- 7.1.1 Overview
- 7.1.2 HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Influenza Testing
- 7.2.1 Overview
- 7.2.2 Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Sexually Transmitted Diseases Testing
- 7.3.1 Overview
- 7.3.2 Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.3.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Sexually Transmitted Diseases Testing
7.4 Hepatitis C Virus Testing
- 7.4.1 Overview
- 7.4.2 Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Tropical Diseases Testing
- 7.5.1 Overview
- 7.5.2 Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  - 7.5.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Tropical Diseases Testing
7.6 Respiratory Infection Testing
- 7.6.1 Overview
- 7.6.2 Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
7.7 Hospital Acquired Infections
- 7.7.1 Overview
- 7.7.2 Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
7.8 Strep
- 7.8.1 Overview
- 7.8.2 Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
7.9 Others
- 7.9.1 Overview
- 7.9.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Technology

8.1 Lateral Flow Assay
- 8.1.1 Overview
- 8.1.2 Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Dipsticks
- 8.2.1 Overview
- 8.2.2 Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Microfluidics
- 8.3.1 Overview
- 8.3.2 Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Molecular Diagnostics
- 8.4.1 Overview
- 8.4.2 Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  - 8.4.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Molecular Diagnostics
    - 8.4.2.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Polymerase Chain Reactions (PCR)
8.5 Immunoassays
- 8.5.1 Overview
- 8.5.2 Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Solid Phase
- 8.6.1 Overview
- 8.6.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Prescription Testing

9.1 Prescription Based Testing
- 9.1.1 Overview
- 9.1.2 Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
9.2 OTC Testing
- 9.2.1 Overview
- 9.2.2 OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Sample

10.1 Blood Sample
- 10.1.1 Overview
- 10.1.2 Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Urine Sample
- 10.2.1 Overview
- 10.2.2 Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Nasal and Oropharyngeal Swabs Sample
- 10.3.1 Overview
- 10.3.2 Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
10.4 Others
- 10.4.1 Overview
- 10.4.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by End User

11.1 Hospitals and Clinics
- 11.1.1 Overview
- 11.1.2 Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million) - by Hospitals and Clinics
11.2 Home Care Settings
- 11.2.1 Overview
- 11.2.2 Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
11.3 Ambulatory and Urgent Care Facilities
- 11.3.1 Overview
- 11.3.2 Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
11.4 Nursing Home and Assisted Living Facilities
- 11.4.1 Overview
- 11.4.2 Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
11.5 Research Laboratories
- 11.5.1 Overview
- 11.5.2 Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
11.6 Diagnostics Centers
- 11.6.1 Overview
- 11.6.2 Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Distribution Channel

12.1 E-Com Platforms
- 12.1.1 Overview
- 12.1.2 E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
12.2 Retail Channel and Pharmacies
- 12.2.1 Overview
- 12.2.2 Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
12.3 Others
- 12.3.1 Overview
- 12.3.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)

13. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Country Analysis

13.1 North America
- 13.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Countries
- 13.1.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis - by Country
  - 13.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis - by Country
  - 13.1.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
    - 13.1.2.2.1 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
    - 13.1.2.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
    - 13.1.2.2.3 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
    - 13.1.2.2.4 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
    - 13.1.2.2.5 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
    - 13.1.2.2.6 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
    - 13.1.2.2.7 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
    - 13.1.2.2.8 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
    - 13.1.2.2.9 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
    - 13.1.2.2.10 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
    - 13.1.2.2.11 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
  - 13.1.2.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
    - 13.1.2.3.1 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
    - 13.1.2.3.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
    - 13.1.2.3.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
    - 13.1.2.3.4 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
    - 13.1.2.3.5 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
    - 13.1.2.3.6 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
    - 13.1.2.3.7 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
    - 13.1.2.3.8 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
    - 13.1.2.3.9 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
    - 13.1.2.3.10 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
    - 13.1.2.3.11 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
  - 13.1.2.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market - Revenue and Forecast to 2031 (US$ Million)
    - 13.1.2.4.1 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
    - 13.1.2.4.2 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
    - 13.1.2.4.3 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
    - 13.1.2.4.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
    - 13.1.2.4.5 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
    - 13.1.2.4.6 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
    - 13.1.2.4.7 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
    - 13.1.2.4.8 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
    - 13.1.2.4.9 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
    - 13.1.2.4.10 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
    - 13.1.2.4.11 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel

14. North America Point-Of-Care Molecular Testing for Infectious Diseases Market - Industry Landscape

14.1 Overview
14.2 Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
14.3 Organic Growth Strategies
- 14.3.1 Overview
14.4 Inorganic Growth Strategies
- 14.4.1 Overview

15. Company Profiles

15.1 Abbott Laboratories
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Agilent Technologies Inc
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Becton Dickinson and Co
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 Bio-Rad Laboratories Inc
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
15.5 Cardinal Health Inc
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 Danaher Corp
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 Cue Health Inc
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 QuidelOrtho Corp
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 Thermo Fisher Scientific Inc
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 F. Hoffmann-La Roche Ltd
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments

16. Appendix

16.1 About The Insight Partners
16.2 Glossary of Terms
- 1.1.1

北米の感染症向けPOC市場規模・予測、地域シェア、動向、成長機会分析レポート

North America Point-of-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis Report

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章北米の感染症向けPOC市場情勢

第5章北米の感染症向けPOC市場力学

第6章北米の感染症向けPOC市場分析

第7章北米の感染症向けPOC分子検査市場分析-疾患別

第8章北米の感染症向けPOC市場分析-技術別

第9章北米感染症向けPOC市場分析-処方箋検査別

第10章北米の感染症用POC市場分析-検体別

第11章北米の感染症向けPOC市場分析：エンドユーザー別

第12章北米の感染症向けPOC市場分析：流通チャネル別

第13章北米の感染症向けPOC市場：国別分析

第14章北米の感染症向けPOC市場：業界情勢

第15章企業プロファイル

第16章付録

List Of Tables

List Of Figures

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape

5. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Key Market Dynamics

6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis

7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Diseases

8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Technology

9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Prescription Testing

10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Sample

11. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by End User

12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Distribution Channel

13. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Country Analysis

14. North America Point-Of-Care Molecular Testing for Infectious Diseases Market - Industry Landscape

15. Company Profiles

16. Appendix

北米の感染症向けPOC市場規模・予測、地域シェア、動向、成長機会分析レポート

North America Point-of-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021-2031), Regional Share, Trend, and Growth Opportunity Analysis Report

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 北米の感染症向けPOC市場情勢

第5章 北米の感染症向けPOC市場力学

第6章 北米の感染症向けPOC市場分析

第7章 北米の感染症向けPOC分子検査市場分析-疾患別

第8章 北米の感染症向けPOC市場分析-技術別

第9章 北米感染症向けPOC市場分析-処方箋検査別

第10章 北米の感染症用POC市場分析-検体別

第11章 北米の感染症向けPOC市場分析：エンドユーザー別

第12章 北米の感染症向けPOC市場分析：流通チャネル別

第13章 北米の感染症向けPOC市場：国別分析

第14章 北米の感染症向けPOC市場：業界情勢

第15章 企業プロファイル

第16章 付録

List Of Tables

List Of Figures

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape

5. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Key Market Dynamics

6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis

7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Diseases

8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Technology

9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Prescription Testing

10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Sample

11. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by End User

12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis - by Distribution Channel

13. North America Point-of-Care Molecular Testing for Infectious Diseases Market - Country Analysis

14. North America Point-Of-Care Molecular Testing for Infectious Diseases Market - Industry Landscape

15. Company Profiles

16. Appendix

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章北米の感染症向けPOC市場情勢

第5章北米の感染症向けPOC市場力学

第6章北米の感染症向けPOC市場分析

第7章北米の感染症向けPOC分子検査市場分析-疾患別

第8章北米の感染症向けPOC市場分析-技術別

第9章北米感染症向けPOC市場分析-処方箋検査別

第10章北米の感染症用POC市場分析-検体別

第11章北米の感染症向けPOC市場分析：エンドユーザー別

第12章北米の感染症向けPOC市場分析：流通チャネル別

第13章北米の感染症向けPOC市場：国別分析

第14章北米の感染症向けPOC市場：業界情勢

第15章企業プロファイル

第16章付録